Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

FLAI induction regimen in elderly patients with acute myeloid leukemia.

Cerrano M, Candoni A, Crisà E, Dubbini MV, D'Ardia S, Zannier ME, Boccadoro M, Audisio E, Bruno B, Ferrero D.

Leuk Lymphoma. 2019 Jun 4:1-2. doi: 10.1080/10428194.2019.1620943. [Epub ahead of print] No abstract available.

PMID:
31159609
2.

Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives.

Coscia M, Vitale C, Cerrano M, Maffini E, Giaccone L, Boccadoro M, Bruno B.

Front Biosci (Landmark Ed). 2019 Jun 1;24:1284-1315.

PMID:
31136980
3.

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, Giai V, Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.

Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.

4.

New Treatment Options for Acute Myeloid Leukemia in 2019.

Cerrano M, Itzykson R.

Curr Oncol Rep. 2019 Feb 4;21(2):16. doi: 10.1007/s11912-019-0764-8. Review.

PMID:
30715623
5.

The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib.

Crisà E, Cilloni D, Elli EM, Martinelli V, Palumbo GA, Pugliese N, Beggiato E, Frairia C, Cerrano M, Lanzarone G, Marchetti M, Mezzabotta M, Boccadoro M, Ferrero D.

Br J Haematol. 2018 Sep;182(5):701-704. doi: 10.1111/bjh.15450. Epub 2018 Jul 9.

PMID:
29984826
6.

Can pegylated interferon improve the outcome of polycythemia vera patients?

Crisà E, Cerrano M, Beggiato E, Benevolo G, Lanzarone G, Manzini PM, Borchiellini A, Riera L, Boccadoro M, Ferrero D.

J Hematol Oncol. 2017 Jan 13;10(1):15. doi: 10.1186/s13045-017-0395-1.

7.

Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta-rearranged myeloproliferative neoplasm.

Cerrano M, Crisà E, Gottardi E, Aguzzi C, Boccadoro M, Ferrero D.

Am J Hematol. 2016 Sep;91(9):E353. doi: 10.1002/ajh.24422. Epub 2016 Jun 20. No abstract available.

8.

Anemia in the Elderly: not Always what it Seems.

Cerrano M, Crisà E, Giai V, Boccadoro M, Ferrero D.

Mediterr J Hematol Infect Dis. 2016 Feb 25;8(1):e2016017. doi: 10.4084/MJHID.2016.017. eCollection 2016.

9.

How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.

Ferrero D, Cerrano M, Crisà E, Aguzzi C, Giai V, Boccadoro M.

Br J Haematol. 2017 Feb;176(4):669-671. doi: 10.1111/bjh.13983. Epub 2016 Feb 23. No abstract available.

PMID:
26914729
10.

Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.

Cerrano M, Crisà E, Pregno P, Aguzzi C, Riccomagno P, Boccadoro M, Ferrero D.

Am J Hematol. 2013 Oct;88(10):838-42. doi: 10.1002/ajh.23501. Epub 2013 Jul 23.

Supplemental Content

Loading ...
Support Center